Compare TLSA & ZSQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TLSA | ZSQR |
|---|---|---|
| Founded | 2013 | 2022 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.1M | 147.9M |
| IPO Year | 2017 | 2020 |
| Metric | TLSA | ZSQR |
|---|---|---|
| Price | $0.68 | $1.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.87 | N/A |
| AVG Volume (30 Days) | ★ 522.3K | 303.6K |
| Earning Date | 05-01-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,363,045.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $1.83 |
| 52 Week High | $1.90 | $16.62 |
| Indicator | TLSA | ZSQR |
|---|---|---|
| Relative Strength Index (RSI) | 46.12 | 30.02 |
| Support Level | $0.57 | N/A |
| Resistance Level | $1.21 | $4.64 |
| Average True Range (ATR) | 0.10 | 0.42 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 55.24 | 1.68 |
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
Z Squared Inc is a computing infrastructure company operating computing equipment and expanding into AI infrastructure. The Company's idea is to build on three principles: guide with power by acquiring operating sites where power is already flowing; build for AI workloads by converting that capacity into AI-ready colocation where the customer brings the compute and runs what it needs; and scale with discipline by deploying conversion capital site by site, against signed contracts and operational readiness.